EP0891429A2 - Transduktionssystem beruhend auf rekombinantem aav-vektor und seine verwendung - Google Patents
Transduktionssystem beruhend auf rekombinantem aav-vektor und seine verwendungInfo
- Publication number
- EP0891429A2 EP0891429A2 EP97918010A EP97918010A EP0891429A2 EP 0891429 A2 EP0891429 A2 EP 0891429A2 EP 97918010 A EP97918010 A EP 97918010A EP 97918010 A EP97918010 A EP 97918010A EP 0891429 A2 EP0891429 A2 EP 0891429A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- rep
- cells
- transduction system
- dna
- aav
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000010361 transduction Methods 0.000 title claims abstract description 31
- 230000026683 transduction Effects 0.000 title claims abstract description 31
- 239000013598 vector Substances 0.000 title description 4
- 239000013607 AAV vector Substances 0.000 claims abstract description 21
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 19
- 210000004027 cell Anatomy 0.000 claims description 43
- 108090000623 proteins and genes Proteins 0.000 claims description 30
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 239000002245 particle Substances 0.000 claims description 11
- 230000002950 deficient Effects 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 5
- 101150044789 Cap gene Proteins 0.000 claims description 4
- 238000001415 gene therapy Methods 0.000 claims description 3
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 description 36
- 241000702421 Dependoparvovirus Species 0.000 description 17
- 241000700605 Viruses Species 0.000 description 11
- 101150066583 rep gene Proteins 0.000 description 10
- 239000013613 expression plasmid Substances 0.000 description 6
- 210000000349 chromosome Anatomy 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 229920000656 polylysine Polymers 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108010039918 Polylysine Proteins 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 241000353621 Eilat virus Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 208000019065 cervical carcinoma Diseases 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229920002714 polyornithine Polymers 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 101150061166 tetR gene Proteins 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- the present invention relates to a transduction system comprising a rep-negative AAV vector and its use.
- Transduction refers to the transmission of genes using viruses as a vector. Transduction is often used to insert genes into the genome
- viruses are e.g. Adeno-associated viruses (AAVs) are used.
- AAVs Adeno-associated viruses
- AAVs are single-stranded DNA viruses belonging to the parvovirus family. For their replication, AAVs need helper viruses, especially adenoviruses or
- AAVs integrate into the host cell genome, particularly at a specific location on chromosome 19.
- the genome of AAVs is linear and has a length of approximately 4680 nucleotides. This comprises two reading frames which code for a structural and a non-structural gene.
- the structural gene is called the cap gene. This is under the control of the P40 promoter and codes for three capsid proteins.
- the non-structural gene is referred to as the rep gene and codes for the Rep proteins, Rep 78, Rep 68, Rep 52 and Rep 40. The former two are expressed under the control of the P5 promoter, while the expression of Rep 52 and Rep 40 is under the control of the P19 promoter.
- the functions of the Rep proteins include in the regulation of replication and transcription of the AAV genome.
- the present invention is therefore based on the object of providing a means by which a foreign DNA can be specifically integrated into the genome of cells.
- the present invention thus relates to a transduction system comprising: (a) a rep-negative AAV vector containing a foreign DNA, and
- the present invention is based on the applicant's finding that AAVs lacking the rep gene do not integrate into the genome of cells.
- rep negative AAV vector refers to any AAV, i.e. Virus particles, and their DNA, which are rep negative. The latter means that there is no or only a defective rep gene.
- Conventional methods can be used to provide a rep-negative AAV vector. For example, an AAV DNA can be changed by specific mutagenesis in the rep gene so that it becomes defective, or the rep gene is deleted by special restriction cleavage and ligation.
- a rep-negative AAV DNA can then be transfected into cells expressing an AAV rep gene, and after infection with a helper virus, rep-negative AAVs, i.e. Virus particles.
- the term "foreign DNA” refers to any DNA that can be integrated in a rep-negative AAV vector.
- the foreign DNA can be non-coding or coding.
- the foreign DNA can be a regulatory element of DNA replication and / or transcription.
- the foreign DNA can code for a diagnostic and / or therapeutic protein. Examples of one therapeutic proteins are tumor necrosis factor, interferons, interleukins, lymphokines, growth factors, plasma proteins and receptors.
- the foreign DNA can be inserted anywhere in the rep-negative AAV vector. It can be advantageous if the foreign DNA is present in or instead of the rep gene. It can also be advantageous if there are several foreign DNAs.
- agent providing AAV Rep protein includes any agent that can provide an AAV Rep protein, particularly Rep 78 or Rep 68, or a portion thereof.
- the agent can be an AAV rep
- rep-DNA Protein or a part of it expressible DNA (rep-DNA). It is favorable if the expression of the rep-DNA is under the control of an inducible promoter, such as an antibiotic or tissue-specific promoter.
- the rep DNA can be comprised of the genome of an AAV virus particle. It is favorable if the genome contains a defective (deleted) cap gene or an inducible one
- the genome and the corresponding AAV virus particle can also be an agent in the above sense.
- the agent can be an AAV-Rep protein, in particular Rep 78 or Rep 68, itself or a part thereof or a fusion protein which contains an AAV-Rep protein or a part thereof.
- Such proteins can be provided by customary methods.
- components (a) and (b) can be connected to one another. Such a connection can be made by conventional methods. Lying z. B. the AAV vector of component (a) as virus
- the AAV vector is modified chemically or enzymatically.
- biotinylated ie biotin or a biotinylated anti-AAV antibody, such as an antibody directed against the AAV proteins VP-1, VP-2 or VP-3, are bound to the AAV vector.
- the rep-expressing DNA is mixed with DNA-binding substances, such as organic polycations, for example polylysine and / or polyornithine, or heterologous polycations with several different, positively charged amino acids.
- An above transduction system is suitable for transducing cells.
- the cells can be of any kind and descent.
- the cells can be present individually or in a bandage, such as a tissue or organ.
- the cells can also be present in or outside an organism. In the latter case, the cells can be kept in culture.
- the cells can be healthy cells, diseased cells such as virus-infected cells or cells infected with microorganisms or single cells, or tumor cells.
- the transduction of the cells can be carried out by conventional methods. Becomes a
- the cells can be infected with the transduction system.
- the transduction system can e.g. can be introduced into the cells by transfection, lipofection or electroporation.
- the cells can be infected with the virus particles.
- the cells can be infected with the AAV vector or the agent and the DNA can be introduced into the cells as indicated above.
- the AAV vector and the agent are each present as DNA, they can be introduced into the cells as indicated above.
- the agent is also in the form of an AAV-Rep protein or a part thereof or as a fusion protein which contains an AAV-Rep protein or a part thereof, the agent can be introduced into the cells, for example by lipofection become.
- the present invention can be used to transduce cells that are inside or outside an organism.
- the present invention is particularly suitable for transducing cells from a tumor material that has been removed without these cells having to be brought into culture beforehand.
- the present invention is therefore ideally suited for use in gene therapy, in particular of monogenic diseases, such as hemoglobin abnormalities, cystic fibrosis, subtypes of Parkinson's disease and hemophilia, of AIDS and cancer.
- monogenic diseases such as hemoglobin abnormalities, cystic fibrosis, subtypes of Parkinson's disease and hemophilia, of AIDS and cancer.
- the invention is illustrated by the following example.
- transduction system As a transduction system according to the invention, one is used in which components (a) and (b) are separated from one another.
- Expression plasmid pRc / CMV (Invitrogen) transfected, which contains an AAV rep gene under the control of the CMV promoter.
- AAV rep gene under the control of the CMV promoter.
- the expression of the AAV-rep gene is determined by an antibody directed against AAV-Rep 78 in the immunoblot.
- Vector i.e. a virus particle that contains an expressible foreign DNA, e.g. contains a DNA coding for a B7 protein.
- a specific integration of the foreign DNA on chromosome 19 is obtained. This is proven by standard procedures. Expression of the B7 protein is also obtained. This is demonstrated by an antibody directed against the B7 protein.
- tetR is a tetracycline repressor
- VP1 6 is the transactivation domain of the VP1 6 molecule of HSV.
- the second expression plasmid, pUHD10-3 contains an AAV rep gene which is under the control of a promoter which is induced by the tetR-VP1 6 fusion protein. This induction is obtained when the tetracycline
- the detection of the transfection is determined via the expression of a neomycin resistance gene on the first expression plasmid and the expression of the rep gene on the second expression plasmid.
- the transfected cells are then infected with the rep-negative AAV vector from (a), which contains a foreign DNA coding for a B7 protein. After removal of tetracycline from the medium a specifi ⁇ specific integration is obtained of the foreign DNA on chromosome 1. 9 This is proven by standard procedures. Expression of the
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19608753 | 1996-03-06 | ||
| DE19608753A DE19608753C1 (de) | 1996-03-06 | 1996-03-06 | Transduktionssystem und seine Verwendung |
| PCT/DE1997/000447 WO1997032989A2 (de) | 1996-03-06 | 1997-03-06 | Transduktionssystem beruhend auf rekombinantem aav-vektor und seine verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP0891429A2 true EP0891429A2 (de) | 1999-01-20 |
Family
ID=7787450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP97918010A Withdrawn EP0891429A2 (de) | 1996-03-06 | 1997-03-06 | Transduktionssystem beruhend auf rekombinantem aav-vektor und seine verwendung |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US6207453B1 (enExample) |
| EP (1) | EP0891429A2 (enExample) |
| JP (1) | JP2000506726A (enExample) |
| DE (1) | DE19608753C1 (enExample) |
| WO (1) | WO1997032989A2 (enExample) |
Families Citing this family (208)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19608753C1 (de) * | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
| WO2004104185A1 (en) * | 2003-05-08 | 2004-12-02 | Xcyte Therapies, Inc. | Generation and isolation of antigen-specific t cells |
| US20070032570A1 (en) * | 2003-11-11 | 2007-02-08 | Canon Kabushiki Kaisha | Ink comprising a block copolymer dispersing agent having a hydrophilic and a hydrophobic segment and an ink-applying process and apparatus using the same |
| US20050281786A1 (en) * | 2004-06-18 | 2005-12-22 | David Poulsen | AAV mediated gene delivery to cochlear cells |
| US20100080784A1 (en) * | 2008-09-12 | 2010-04-01 | Torrey Pines Institute For Molecular Studies | Methods for treating cachexia and lymphopenia |
| EP2841572B1 (en) | 2012-04-27 | 2019-06-19 | Duke University | Genetic correction of mutated genes |
| US9828582B2 (en) | 2013-03-19 | 2017-11-28 | Duke University | Compositions and methods for the induction and tuning of gene expression |
| IL292038B2 (en) | 2014-04-23 | 2024-12-01 | Juno Therapeutics Inc | Methods for enriching or producing immune cell populations for adoptive therapy |
| US10738278B2 (en) | 2014-07-15 | 2020-08-11 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
| TWI751102B (zh) | 2014-08-28 | 2022-01-01 | 美商奇諾治療有限公司 | 對ｃｄ１９具專一性之抗體及嵌合抗原受體 |
| BR112017008042A2 (pt) | 2014-10-20 | 2017-12-26 | Juno Therapeutics Inc | métodos e composições para dosagem em terapia de célula adotiva |
| JP6740234B2 (ja) | 2014-11-05 | 2020-08-12 | ジュノー セラピューティクス インコーポレイテッド | 形質導入および細胞プロセシングのための方法 |
| EP3227323B1 (en) | 2014-12-03 | 2020-08-05 | Juno Therapeutics, Inc. | Methods and compositions for adoptive cell therapy |
| US20160208018A1 (en) | 2015-01-16 | 2016-07-21 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for ror1 |
| US10676726B2 (en) | 2015-02-09 | 2020-06-09 | Duke University | Compositions and methods for epigenome editing |
| WO2016166568A1 (en) | 2015-04-16 | 2016-10-20 | Juno Therapeutics Gmbh | Methods, kits and apparatus for expanding a population of cells |
| MX2017015239A (es) | 2015-05-29 | 2018-02-19 | Juno Therapeutics Inc | Composicion y metodos para regular interacciones inhibitorias en celulas geneticamente modificadas. |
| MA42895A (fr) | 2015-07-15 | 2018-05-23 | Juno Therapeutics Inc | Cellules modifiées pour thérapie cellulaire adoptive |
| WO2017066497A2 (en) | 2015-10-13 | 2017-04-20 | Duke University | Genome engineering with type i crispr systems in eukaryotic cells |
| MA45489A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés de culture de cellules, kits et appareil associés |
| KR102908806B1 (ko) | 2015-10-22 | 2026-01-07 | 주노 테라퓨틱스 게엠베하 | 세포의 배양 방법 및 이를 위한 키트와 장치 |
| US11020429B2 (en) | 2015-11-05 | 2021-06-01 | Juno Therapeutics, Inc. | Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy |
| MX2018005618A (es) | 2015-11-05 | 2018-08-01 | Juno Therapeutics Inc | Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados. |
| US12214054B2 (en) | 2015-11-30 | 2025-02-04 | Duke University | Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use |
| US20200297760A1 (en) | 2015-12-03 | 2020-09-24 | Juno Therapeutics, Inc. | Compositions and methods for reducing immune responses against chimeric antigen receptors |
| MX2018006789A (es) | 2015-12-03 | 2019-02-13 | Juno Therapeutics Inc | Receptores quimericos modificados y composiciones y metodos relacionados. |
| WO2017096331A1 (en) | 2015-12-04 | 2017-06-08 | Juno Therapeutics, Inc. | Methods and compositions related to toxicity associated with cell therapy |
| MA43759A (fr) | 2016-03-16 | 2018-11-28 | Jason Connor | Procédés de conception adaptative d'un régime de traitement et traitements associés |
| WO2017161208A1 (en) | 2016-03-16 | 2017-09-21 | Juno Therapeutics, Inc. | Methods for determining dosing of a therapeutic agent and related treatments |
| CN109476743A (zh) | 2016-03-22 | 2019-03-15 | 西雅图儿童医院(以西雅图儿童研究所名义营业) | 预防或缓解毒性的早期干预方法 |
| EP3443081A4 (en) | 2016-04-13 | 2019-10-30 | Duke University | CRISPR / CAS9-BASED REPRESSORS FOR IN VIVO SHUT-OFF OF GEN-TARGETS AND METHOD OF USE |
| EP3452499A2 (en) | 2016-05-06 | 2019-03-13 | Juno Therapeutics, Inc. | Genetically engineered cells and methods of making the same |
| WO2017210689A1 (en) | 2016-06-03 | 2017-12-07 | Memorial Sloan-Kettering Cancer Center | Adoptive cell therapies as early treatment options |
| WO2017214207A2 (en) | 2016-06-06 | 2017-12-14 | Juno Therapeutics, Inc. | Methods for the treatment of b cell malignancies using adoptive cell therapy |
| JP7054397B2 (ja) | 2016-06-27 | 2022-04-13 | ジュノー セラピューティクス インコーポレイテッド | Ｍｈｃ－ｅ拘束性エピトープ、結合分子ならびに関連する方法および使用 |
| US20200182884A1 (en) | 2016-06-27 | 2020-06-11 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
| JP7490211B2 (ja) | 2016-07-19 | 2024-05-27 | デューク ユニバーシティ | Ｃｐｆ１に基づくゲノム編集の治療適用 |
| JP7295795B2 (ja) | 2016-07-29 | 2023-06-21 | ジュノー セラピューティクス インコーポレイテッド | 免疫調節ポリペプチドならびに関連する組成物および方法 |
| MA45784A (fr) | 2016-07-29 | 2019-06-05 | Juno Therapeutics Inc | Anticorps anti-idiotypes dirigés contre anti-cd19 anticorps |
| MX2019002765A (es) | 2016-09-12 | 2019-05-09 | Juno Therapeutics Inc | Montajes de bolsa de biorreactor de perfusion. |
| CN110087657A (zh) | 2016-09-28 | 2019-08-02 | 阿托莎遗传股份有限公司 | 过继细胞治疗的方法 |
| KR20190062505A (ko) | 2016-10-03 | 2019-06-05 | 주노 쎄러퓨티크스 인코퍼레이티드 | Hpv-특이적 결합 분자 |
| EP3525803B1 (en) | 2016-10-13 | 2022-12-07 | Juno Therapeutics, Inc. | Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators |
| CA3042049A1 (en) | 2016-11-03 | 2018-05-11 | Juno Therapeutics, Inc. | Combination therapy of a t cell therapy and a btk inhibitor |
| MA46716A (fr) | 2016-11-03 | 2019-09-11 | Juno Therapeutics Inc | Polythérapie de thérapie cellulaire et d'inhibiteur de la microglie |
| WO2018102612A1 (en) | 2016-12-02 | 2018-06-07 | Juno Therapeutics, Inc. | Engineered b cells and related compositions and methods |
| JP2019536460A (ja) | 2016-12-03 | 2019-12-19 | ジュノー セラピューティクス インコーポレイテッド | Ｃａｒ−ｔ細胞の調節方法 |
| US20200078400A1 (en) | 2016-12-03 | 2020-03-12 | Juno Therapeutics, Inc. | Methods for determining car-t cells dosing |
| US11590167B2 (en) | 2016-12-03 | 2023-02-28 | Juno Therapeutic, Inc. | Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors |
| EP3571221A2 (en) | 2017-01-20 | 2019-11-27 | Juno Therapeutics GmbH | Cell surface conjugates and related cell compositions and methods |
| IL268349B2 (en) | 2017-02-17 | 2024-08-01 | Hutchinson Fred Cancer Res | Combination therapies for treatment of bcma-related cancers and autoimmune disorders |
| MX2019010171A (es) | 2017-02-27 | 2019-10-15 | Juno Therapeutics Inc | Composiciones, articulos de fabricacion y metodos relacionados con la dosificacion en la terapia celular. |
| CN110913690A (zh) | 2017-03-14 | 2020-03-24 | 朱诺治疗学股份有限公司 | 用于低温储存的方法 |
| BR102018006205A2 (pt) | 2017-03-28 | 2021-03-23 | Cell Design Labs, Inc. | Polipeptídeos quiméricos e métodos de alterar a localização da membrana dos mesmos |
| MX2019012017A (es) | 2017-04-07 | 2020-02-12 | Juno Therapeutics Inc | Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados. |
| CN110709700A (zh) | 2017-04-14 | 2020-01-17 | 朱诺治疗学股份有限公司 | 评估细胞表面糖基化的方法 |
| AU2018260380B2 (en) | 2017-04-27 | 2025-02-13 | Juno Therapeutics Gmbh | Oligomeric particle reagents and methods of use thereof |
| PL3618842T3 (pl) | 2017-05-01 | 2024-02-19 | Juno Therapeutics, Inc. | Kombinacja terapii komórkowej i związku immunomodulującego |
| IL327498A (en) | 2017-06-02 | 2026-05-01 | Juno Therapeutics Inc | Articles of manufacture and methods for treatment using adoptive cell therapy |
| EP3631468A1 (en) | 2017-06-02 | 2020-04-08 | Juno Therapeutics, Inc. | Articles of manufacture and methods related to toxicity associated with cell therapy |
| CN110997902B (zh) | 2017-06-20 | 2021-11-30 | 居里研究所 | Suv39h1缺陷的免疫细胞 |
| CN111050545A (zh) | 2017-06-29 | 2020-04-21 | 朱诺治疗学股份有限公司 | 评估与免疫疗法相关的毒性的小鼠模型 |
| EP4549554A3 (en) | 2017-07-29 | 2025-08-06 | Juno Therapeutics, Inc. | Reagents for expanding cells expressing recombinant receptors |
| KR102755437B1 (ko) | 2017-08-09 | 2025-01-20 | 주노 쎄러퓨티크스 인코퍼레이티드 | 유전자 조작된 세포 조성물 및 관련 조성물의 제조 방법 |
| EP4516896A3 (en) | 2017-08-09 | 2025-05-14 | Juno Therapeutics, Inc. | Methods and compositions for preparing genetically engineered cells |
| WO2019046832A1 (en) | 2017-09-01 | 2019-03-07 | Juno Therapeutics, Inc. | GENE EXPRESSION AND EVALUATION OF RISK OF DEVELOPMENT OF TOXICITY FOLLOWING CELL THERAPY |
| MA50079A (fr) | 2017-09-07 | 2020-07-15 | Juno Therapeutics Inc | Procédés d'identification de caractéristiques cellulaires relatives à des réponses associées à une thérapie cellulaire |
| US11952408B2 (en) | 2017-10-03 | 2024-04-09 | Juno Therapeutics, Inc. | HPV-specific binding molecules |
| CA3081456A1 (en) | 2017-11-01 | 2019-05-09 | Editas Medicine, Inc. | Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy |
| US11066475B2 (en) | 2017-11-01 | 2021-07-20 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides |
| CA3080509A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Process for producing a t cell composition |
| JP7357626B2 (ja) | 2017-11-01 | 2023-10-06 | ジュノー セラピューティクス インコーポレイテッド | 操作された細胞の治療用組成物を生成するためのプロセス |
| US11851679B2 (en) | 2017-11-01 | 2023-12-26 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
| WO2019089858A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| MA49911A (fr) | 2017-11-01 | 2020-06-24 | Juno Therapeutics Inc | Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b |
| WO2019089848A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
| JP2021502077A (ja) | 2017-11-06 | 2021-01-28 | エディタス・メディシン，インコーポレイテッド | 免疫療法のためのｔ細胞におけるｃｂｌｂのｃｒｉｓｐｒ−ｃａｓ９編集のための方法、組成物および構成要素 |
| AU2018359907A1 (en) | 2017-11-06 | 2020-05-07 | Fred Hutchinson Cancer Center | Combination of a cell therapy and a gamma secretase inhibitor |
| US20200330983A1 (en) | 2017-11-10 | 2020-10-22 | Juno Therapeutics, Inc. | Closed-system cryogenic vessels |
| MA51210A (fr) | 2017-12-01 | 2020-10-07 | Juno Therapeutics Inc | Procédés de dosage et de modulation de cellules génétiquement modifiées |
| BR112020011223A2 (pt) | 2017-12-08 | 2020-11-17 | Juno Therapeutics Inc | marcadores fenotípicos para terapia celular e mé-todos relacionados |
| AU2018379091A1 (en) | 2017-12-08 | 2020-06-25 | Juno Therapeutics, Inc. | Serum-free media formulation for culturing cells and methods of use thereof |
| CN119193493A (zh) | 2017-12-08 | 2024-12-27 | 朱诺治疗学股份有限公司 | 生产工程化t细胞组合物的过程 |
| EP3724225A1 (en) | 2017-12-15 | 2020-10-21 | Juno Therapeutics, Inc. | Anti-cct5 binding molecules and methods of use thereof |
| WO2019126358A1 (en) | 2017-12-22 | 2019-06-27 | Cell Design Labs, Inc. | Single- and multi-chain chimeric antigen receptors |
| US12509492B2 (en) | 2018-01-19 | 2025-12-30 | Duke University | Genome engineering with CRISPR-Cas systems in eukaryotes |
| CN111971059A (zh) | 2018-01-31 | 2020-11-20 | 细胞基因公司 | 使用过继细胞疗法和检查点抑制剂的组合疗法 |
| WO2019170845A1 (en) | 2018-03-09 | 2019-09-12 | Ospedale San Raffaele S.R.L. | Il-1 antagonist and toxicity induced by cell therapy |
| US12280119B2 (en) | 2018-03-23 | 2025-04-22 | Kite Pharma, Inc. | Chimeric transmembrane proteins and uses thereof |
| CN112566698A (zh) | 2018-04-05 | 2021-03-26 | 朱诺治疗学股份有限公司 | T细胞受体和表达该t细胞受体的工程化细胞 |
| CN112585276A (zh) | 2018-04-05 | 2021-03-30 | 朱诺治疗学股份有限公司 | 产生表达重组受体的细胞的方法和相关组合物 |
| CN112585277A (zh) | 2018-04-05 | 2021-03-30 | 朱诺治疗学股份有限公司 | 表达重组受体的t细胞、相关多核苷酸和方法 |
| BR112020022185A2 (pt) | 2018-05-03 | 2021-02-02 | Juno Therapeutics Inc | terapia de combinação de uma terapia de células t do receptor de antígeno quimérico (car) e um inibidor de quinase |
| CN112368298A (zh) | 2018-06-22 | 2021-02-12 | 凯德药业股份有限公司 | 嵌合跨膜蛋白及其用途 |
| BR112021002390A2 (pt) | 2018-08-09 | 2021-05-11 | Juno Therapeutics Inc | processos para gerar células modificadas e suas composições |
| CN112805378A (zh) | 2018-08-09 | 2021-05-14 | 朱诺治疗学股份有限公司 | 用于评估整合核酸的方法 |
| JP7504891B2 (ja) | 2018-09-11 | 2024-06-24 | ジュノー セラピューティクス インコーポレイテッド | 操作された細胞組成物のマススペクトロメトリー分析のための方法 |
| CA3115298A1 (en) | 2018-10-12 | 2020-04-16 | Theradaptive, Inc. | Polypeptides including a beta-tricalcium phosphate-binding sequence and uses thereof |
| WO2020089343A1 (en) | 2018-10-31 | 2020-05-07 | Juno Therapeutics Gmbh | Methods for selection and stimulation of cells and apparatus for same |
| CN119569895A (zh) | 2018-11-01 | 2025-03-07 | 朱诺治疗学股份有限公司 | G蛋白偶合受体c类5族成员d(gprc5d)特异性嵌合抗原受体 |
| US12473345B2 (en) | 2018-11-01 | 2025-11-18 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen |
| US20210393691A1 (en) | 2018-11-06 | 2021-12-23 | Juno Therapeutics, Inc. | Process for producing genetically engineered t cells |
| CN113573719A (zh) | 2018-11-08 | 2021-10-29 | 朱诺治疗学股份有限公司 | 治疗和t细胞调节的方法和组合 |
| BR112021009420A2 (pt) | 2018-11-16 | 2021-11-23 | Juno Therapeutics Inc | Métodos de dosagem de células t manipuladas para o tratamento de malignidades de células b |
| EP4427810A3 (en) | 2018-11-30 | 2024-12-04 | Juno Therapeutics, Inc. | Methods for treatment using adoptive cell therapy |
| KR20210110811A (ko) | 2018-11-30 | 2021-09-09 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 요법에서 ｂ 세포 악성 종양의 투약 및 치료 방법 |
| EA202192103A1 (ru) | 2019-01-29 | 2021-12-15 | Джуно Терапьютикс, Инк. | Антитела и химерные антигенные рецепторы, специфичные к орфанному рецептору типа рецеторной тирозинкиназы 1 (ror1) |
| TWI887234B (zh) | 2019-04-14 | 2025-06-21 | 美國公爵大學 | 治療杜興氏（ｄｕｃｈｅｎｎｅ）肌肉失養症之大型突變熱點之ａａｖ載體介導之刪除 |
| SG11202111372VA (en) | 2019-05-01 | 2021-11-29 | Juno Therapeutics Inc | Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods |
| CA3136737A1 (en) | 2019-05-01 | 2020-11-05 | Juno Therapeutics, Inc. | Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods |
| US20220228101A1 (en) | 2019-06-07 | 2022-07-21 | Juno Therapeutics, Inc. | Automated t cell culture |
| SG11202113356XA (en) | 2019-06-12 | 2021-12-30 | Juno Therapeutics Inc | Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein |
| CN114391021B (zh) | 2019-06-21 | 2026-01-16 | 凯德药业股份有限公司 | TGF-β受体和使用方法 |
| EP4003407A1 (en) | 2019-07-23 | 2022-06-01 | Mnemo Therapeutics | Immune cells defective for suv39h1 |
| KR20220066892A (ko) | 2019-08-22 | 2022-05-24 | 주노 쎄러퓨티크스 인코퍼레이티드 | Ｔ 세포 요법 및 제스트 동족체 2의 인핸서 (ｅｚｈ2) 억제제의 병용 요법 및 관련 방법 |
| CN114600172A (zh) | 2019-08-30 | 2022-06-07 | 朱诺治疗学股份有限公司 | 用于将细胞分类的机器学习方法 |
| EP4025698A1 (en) | 2019-09-03 | 2022-07-13 | Sana Biotechnology, Inc. | Cd24-associated particles and related methods and uses thereof |
| US20220372516A1 (en) | 2019-10-11 | 2022-11-24 | Takara Bio Inc. | siRNA EXPRESSION VECTOR |
| MX2022005145A (es) | 2019-10-30 | 2022-06-29 | Juno Therapeutics Gmbh | Dispositivos de estimulación y/o selección celular y método de uso. |
| US20220412954A1 (en) | 2019-11-05 | 2022-12-29 | Juno Therapeutics, Inc. | Methods of determining attributes of therapeutic t cell compositions |
| EP4054623A1 (en) | 2019-11-07 | 2022-09-14 | Juno Therapeutics, Inc. | Combination of a t cell therapy and (s)-3-[4-(4-morpholin-4 ylmethyl-benzyloxy)-l-oxo-l,3-dihydro-isoindol-2-yl]- piperidine-2,6-dione |
| WO2021113780A1 (en) | 2019-12-06 | 2021-06-10 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods |
| WO2021113776A1 (en) | 2019-12-06 | 2021-06-10 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods |
| EP4070097A1 (en) | 2019-12-06 | 2022-10-12 | Juno Therapeutics, Inc. | Methods related to toxicity and response associated with cell therapy for treating b cell malignancies |
| US12665049B2 (en) | 2020-01-17 | 2026-06-23 | AskBio, Inc. | Systems and methods for synthetic regulatory sequence design or production |
| US20230071910A1 (en) | 2020-01-24 | 2023-03-09 | Juno Therapeutics, Inc. | Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in adoptive cell therapy |
| CA3169672A1 (en) | 2020-02-12 | 2021-08-19 | Juno Therapeutics, Inc. | Cd19-directed chimeric antigen receptor t cell compositions and methods and uses thereof |
| JP2023519099A (ja) | 2020-02-12 | 2023-05-10 | ジュノー セラピューティクス インコーポレイテッド | Ｂｃｍａ指向性キメラ抗原受容体ｔ細胞組成物ならびにその方法および使用 |
| IL297147B1 (en) | 2020-04-10 | 2026-05-01 | Juno Therapeutics Inc | Methods and uses related to engineered cell therapy with a chimeric antigen receptor directed against a B-cell maturation antigen |
| BR112022020809A2 (pt) | 2020-04-15 | 2023-02-23 | Theradaptive Inc | Composições e métodos para entrega terapêutica direcionada ao osso |
| CA3181399A1 (en) | 2020-04-28 | 2021-11-04 | Juno Therapeutics, Inc. | Combination of bcma-directed t cell therapy and an immunomodulatory compound |
| KR20230024283A (ko) | 2020-05-13 | 2023-02-20 | 주노 쎄러퓨티크스 인코퍼레이티드 | 임상 반응과 관련된 특징을 식별하는 방법 및 이의 용도 |
| KR20230022868A (ko) | 2020-05-13 | 2023-02-16 | 주노 쎄러퓨티크스 인코퍼레이티드 | 재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법 |
| US20230190871A1 (en) | 2020-05-20 | 2023-06-22 | Sana Biotechnology, Inc. | Methods and compositions for treatment of viral infections |
| EP4171616A1 (en) | 2020-06-26 | 2023-05-03 | Juno Therapeutics GmbH | Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods |
| CA3188656A1 (en) | 2020-07-17 | 2022-01-20 | Simurx, Inc. | Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods |
| JP7886313B2 (ja) | 2020-07-30 | 2026-07-07 | アンスティテュ・クリー | Ｓｏｃｓ１に欠陥のある免疫細胞 |
| KR20230095918A (ko) | 2020-08-05 | 2023-06-29 | 주노 쎄러퓨티크스 인코퍼레이티드 | Ror1-표적 결합 도메인에 대한 항이디오타입 항체 및 관련 조성물 및 방법 |
| WO2022047316A1 (en) | 2020-08-28 | 2022-03-03 | Sana Biotechnology, Inc. | Modified anti-viral binding agents |
| GB202013940D0 (en) | 2020-09-04 | 2020-10-21 | Synpromics Ltd | Regulatory nucleic acid sequences |
| US20230374542A1 (en) | 2020-10-07 | 2023-11-23 | Asklepios Biopharmaceutical, Inc. | Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 (lgmd21) |
| WO2022082030A2 (en) | 2020-10-15 | 2022-04-21 | Gritstone Bio, Inc. | Antigen-binding proteins and related methods of use |
| WO2022133030A1 (en) | 2020-12-16 | 2022-06-23 | Juno Therapeutics, Inc. | Combination therapy of a cell therapy and a bcl2 inhibitor |
| KR20230151513A (ko) | 2021-01-11 | 2023-11-01 | 사나 바이오테크놀로지, 인크. | Cd8 표적 바이러스 벡터의 용도 |
| WO2022155503A1 (en) | 2021-01-14 | 2022-07-21 | Gritstone Bio, Inc. | Multi-specific antibodies and methods of use |
| KR20230165771A (ko) | 2021-03-03 | 2023-12-05 | 주노 쎄러퓨티크스 인코퍼레이티드 | T 세포 요법 및 dgk 억제제의 조합 |
| US20240168012A1 (en) | 2021-03-22 | 2024-05-23 | Juno Therapeutics, Inc. | Methods of determining potency of a therapeutic cell composition |
| IL307257A (en) | 2021-03-29 | 2023-11-01 | Juno Therapeutics Inc | A combination of car cell therapy and an immunomodulatory compound for the treatment of lymphoma |
| CN117858719A (zh) | 2021-03-29 | 2024-04-09 | 朱诺治疗学股份有限公司 | 使用检查点抑制剂疗法和car t细胞疗法的组合进行给药和治疗的方法 |
| CN118201618A (zh) | 2021-04-16 | 2024-06-14 | 细胞基因公司 | 与bcma定向t细胞疗法的组合疗法 |
| CN117916256A (zh) | 2021-05-06 | 2024-04-19 | 朱诺治疗学有限公司 | 用于刺激和转导t细胞的方法 |
| US20250304915A1 (en) | 2021-05-25 | 2025-10-02 | Institut Curie | Myeloid Cells Overexpressing BCL2 |
| WO2022261061A1 (en) | 2021-06-08 | 2022-12-15 | Kite Pharma, Inc. | Gpc3 binding molecules |
| US20240254483A1 (en) | 2021-07-30 | 2024-08-01 | Tune Therapeutics, Inc. | Compositions and methods for modulating expression of frataxin (fxn) |
| AU2022318664A1 (en) | 2021-07-30 | 2024-02-29 | Tune Therapeutics, Inc. | Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) |
| EP4381081A1 (en) | 2021-08-04 | 2024-06-12 | Sana Biotechnology, Inc. | Use of cd4-targeted viral vectors |
| US20260083848A1 (en) | 2021-11-03 | 2026-03-26 | Viracta Therapeutics, Inc. | Combination of car t-cell therapy with btk inhibitors and methods of use thereof |
| WO2023081735A1 (en) | 2021-11-03 | 2023-05-11 | Celgene Corporation | Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma |
| WO2023081900A1 (en) | 2021-11-08 | 2023-05-11 | Juno Therapeutics, Inc. | Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods |
| JP2025501272A (ja) | 2021-12-28 | 2025-01-17 | ムネモ・セラピューティクス | 不活性化されたｓｕｖ３９ｈ１及び改変ｔｃｒを有する免疫細胞 |
| US20250082777A1 (en) | 2022-01-10 | 2025-03-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| EP4463549A2 (en) | 2022-01-14 | 2024-11-20 | Tune Therapeutics, Inc. | Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression |
| US20250134999A1 (en) | 2022-01-14 | 2025-05-01 | Tune Therapeutics, Inc. | Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation |
| WO2023150518A1 (en) | 2022-02-01 | 2023-08-10 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
| WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| IL314801A (en) | 2022-02-22 | 2024-10-01 | Juno Therapeutics Inc | Proteinase 3 (PR3) Chimeric Autoantigen Receptor T Cells and Related Methods and Uses |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| WO2023201133A1 (en) | 2022-04-14 | 2023-10-19 | Board Of Regents Of The University Of Nebraska | Cell therapy for alzheimer's disease |
| US20250297282A1 (en) | 2022-05-05 | 2025-09-25 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
| US20250302954A1 (en) | 2022-05-11 | 2025-10-02 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| EP4279085A1 (en) | 2022-05-20 | 2023-11-22 | Mnemo Therapeutics | Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease |
| WO2023230581A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Methods of manufacturing t cell therapies |
| US20250345432A1 (en) | 2022-05-25 | 2025-11-13 | Celgene Corporation | Method for predicting response to a t cell therapy |
| JP2025521543A (ja) | 2022-06-22 | 2025-07-10 | ジュノー セラピューティクス インコーポレイテッド | Ｃｄ１９標的ｃａｒ ｔ細胞のセカンドライン治療のための処置方法 |
| CA3260237A1 (en) | 2022-06-24 | 2023-12-28 | Tune Therapeutics, Inc. | Compositions, systems and methods for reducing low-density lipoprotein by targeted gene repression |
| WO2024006960A1 (en) | 2022-06-29 | 2024-01-04 | Juno Therapeutics, Inc. | Lipid nanoparticles for delivery of nucleic acids |
| EP4554967A2 (en) | 2022-07-12 | 2025-05-21 | Tune Therapeutics, Inc. | Compositions, systems, and methods for targeted transcriptional activation |
| US20260027145A1 (en) | 2022-07-27 | 2026-01-29 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| EP4565262A2 (en) | 2022-08-05 | 2025-06-11 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for gprc5d and bcma |
| WO2024040254A2 (en) | 2022-08-19 | 2024-02-22 | Tune Therapeutics, Inc. | Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression |
| US20260061051A1 (en) | 2022-08-26 | 2026-03-05 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3) |
| KR20250061756A (ko) | 2022-09-08 | 2025-05-08 | 주노 쎄러퓨티크스 인코퍼레이티드 | T 세포 요법과 연속적 또는 간헐적 dgk 억제제 투여의 조합 |
| JP2025531268A (ja) | 2022-09-19 | 2025-09-19 | チューン セラピューティクス インコーポレイテッド | Ｔ細胞機能を調節するための組成物、システム、および方法 |
| WO2024062138A1 (en) | 2022-09-23 | 2024-03-28 | Mnemo Therapeutics | Immune cells comprising a modified suv39h1 gene |
| US20260166082A1 (en) | 2022-11-02 | 2026-06-18 | Celgene Corporation | Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy |
| WO2024100604A1 (en) | 2022-11-09 | 2024-05-16 | Juno Therapeutics Gmbh | Methods for manufacturing engineered immune cells |
| CN121100267A (zh) | 2022-12-09 | 2025-12-09 | 朱诺治疗学股份有限公司 | 使用全息成像预测细胞表型的机器学习方法 |
| US20260207667A1 (en) | 2022-12-13 | 2026-07-23 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof |
| WO2024163683A2 (en) | 2023-02-01 | 2024-08-08 | Tune Therapeutics, Inc. | Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist) |
| WO2024163678A2 (en) | 2023-02-01 | 2024-08-08 | Tune Therapeutics, Inc. | Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods |
| WO2024182516A1 (en) | 2023-02-28 | 2024-09-06 | Juno Therapeutics, Inc. | Cell therapy for treating systemic autoimmune diseases |
| KR20250169631A (ko) | 2023-04-18 | 2025-12-03 | 주노 쎄러퓨티크스 인코퍼레이티드 | 치료 세포 조성물의 효력을 평가하기 위한 세포독성 검정 |
| EP4716851A2 (en) | 2023-05-23 | 2026-04-01 | Juno Therapeutics, Inc. | Activation markers of t cells and method for assessing t cell activation |
| EP4754248A1 (en) | 2023-07-31 | 2026-06-10 | Tune Therapeutics, Inc. | Compositions and methods for multiplexed activation and repression of t cell gene expression |
| CN121909284A (zh) | 2023-07-31 | 2026-04-21 | 图恩疗法股份有限公司 | 用于调节il-2基因表达的组合物和方法 |
| WO2025038494A1 (en) | 2023-08-11 | 2025-02-20 | Tune Therapeutics, Inc. | Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation |
| WO2025059073A1 (en) | 2023-09-11 | 2025-03-20 | Tune Therapeutics, Inc. | Epigenetic editing methods and systems for differentiating stem cells |
| EP4777540A1 (en) | 2023-09-13 | 2026-07-22 | Juno Therapeutics, Inc. | Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses |
| KR20260088542A (ko) | 2023-10-06 | 2026-06-12 | 주노 쎄러퓨티크스 인코퍼레이티드 | Gprc5d-표적화 car을 발현하는 세포 요법을 사용한 조합 요법 및 관련 방법 및 용도 |
| WO2025147545A1 (en) | 2024-01-03 | 2025-07-10 | Juno Therapeutics, Inc. | Lipid nanoparticles for delivery of nucleic acids and related methods and uses |
| WO2025163107A1 (en) | 2024-02-01 | 2025-08-07 | Institut Gustave Roussy | Immune cells defective for znf217 and uses thereof |
| WO2025184421A1 (en) | 2024-02-28 | 2025-09-04 | Juno Therapeutics, Inc. | Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods |
| WO2026008700A1 (en) | 2024-07-03 | 2026-01-08 | Immunofusion Bv | Il7r alpha signalling domain, chimeric antigen receptor and uses thereof |
| WO2026015647A1 (en) | 2024-07-09 | 2026-01-15 | Tune Therapeutics, Inc. | Compositions, systems, and methods for cell differentiation using targeted gene activation of dll4 and/or vcam1 |
| WO2026020055A2 (en) | 2024-07-18 | 2026-01-22 | Juno Therapeutics, Inc. | Methods for assessing exosomes in a cell composition and related uses |
| WO2026025092A1 (en) | 2024-07-26 | 2026-01-29 | Juno Therapeutics, Inc. | Synthetic promoters for t cell expression |
| WO2026064753A1 (en) | 2024-09-23 | 2026-03-26 | Tune Therapeutics, Inc. | Dna methyltransferase-like protein (dnmt3l) or dna methyltransferase 3a (dnmt3a) repressor systems for epigenetic editing |
| WO2026161895A1 (en) | 2025-01-27 | 2026-07-30 | Tune Therapeutics, Inc. | Compositions, systems, and methods for epigenetic regulation of lipoprotein a (lpa) gene expression |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5436146A (en) * | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| AU7906691A (en) * | 1990-05-23 | 1991-12-10 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Adeno-associated virus (aav)-based eucaryotic vectors |
| US5587308A (en) * | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
| US5478745A (en) * | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
| WO1994021808A1 (de) * | 1993-03-19 | 1994-09-29 | Boehringer Ingelheim International Gmbh | Verfahren zur herstellung von krebsvakzinen |
| US5693531A (en) * | 1993-11-24 | 1997-12-02 | The United States Of America As Represented By The Department Of Health And Human Services | Vector systems for the generation of adeno-associated virus particles |
| FR2716893B1 (fr) * | 1994-03-03 | 1996-04-12 | Rhone Poulenc Rorer Sa | Virus recombinants, leur préparation et leur utilisation thérapeutique. |
| US6342390B1 (en) * | 1994-11-23 | 2002-01-29 | The United States Of America As Represented By The Secretary Of Health And Human Services | Lipid vesicles containing adeno-associated virus rep protein for transgene integration and gene therapy |
| DE19608753C1 (de) * | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
-
1996
- 1996-03-06 DE DE19608753A patent/DE19608753C1/de not_active Expired - Fee Related
-
1997
- 1997-03-06 EP EP97918010A patent/EP0891429A2/de not_active Withdrawn
- 1997-03-06 JP JP9531353A patent/JP2000506726A/ja not_active Ceased
- 1997-03-06 US US09/142,289 patent/US6207453B1/en not_active Expired - Fee Related
- 1997-03-06 WO PCT/DE1997/000447 patent/WO1997032989A2/de not_active Ceased
-
2001
- 2001-01-31 US US09/773,302 patent/US6440742B1/en not_active Expired - Fee Related
-
2002
- 2002-08-12 US US10/218,280 patent/US20020192826A1/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| See references of WO9732989A2 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1997032989A3 (de) | 1998-01-15 |
| US20020028514A1 (en) | 2002-03-07 |
| WO1997032989A2 (de) | 1997-09-12 |
| US6207453B1 (en) | 2001-03-27 |
| JP2000506726A (ja) | 2000-06-06 |
| US6440742B1 (en) | 2002-08-27 |
| US20020192826A1 (en) | 2002-12-19 |
| DE19608753C1 (de) | 1997-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE19608753C1 (de) | Transduktionssystem und seine Verwendung | |
| DE19905501B4 (de) | Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels | |
| DE69433592T2 (de) | Die erzielung hoher titer des rekombinanten aav-vektors | |
| DE69615650T2 (de) | Virale vektoren für die gentherapie | |
| EP1315798A2 (de) | Wirtszellen zur verpackung von rekombinantem adeno-assoziiertem virus (raav), verfahren zu ihrer herstellung und deren verwendung | |
| DE69637432T2 (de) | Adenovirale vektoren für die gentherapie | |
| DE69616559T2 (de) | Hilfsvirus für die herstellung von rekombinanten virusvektoren | |
| DE69824859T2 (de) | Methoden zur erhöhung der effizienz rekombinanter aav produkte | |
| EP1097232A1 (de) | Expressionssysteme enthaltend chimäre promotoren mit bindungsstellen für rekombinante transkriptionsfaktoren | |
| EP0746624B1 (de) | Vektor für die leberspezifische genexpression | |
| DE19751587A1 (de) | Onkogen- oder virusgesteuerte Expressionssysteme | |
| DE19617851A1 (de) | Nukleinsäurekonstrukte mit Genen kodierend für Transportsignale | |
| EP0934423B1 (de) | Aav-dna mit helfervirus-sequenzen | |
| EP1448782A1 (de) | Optimierte herstellung von viralen, von parvoviren abgeleiteten vektoren in verpackungs- und produktionszellen durch hsv-infektion oder behandlung mit inhibitoren der dna-methylierung | |
| Rupprecht et al. | Controlled removal of a nonviral episomal vector from transfected cells | |
| EP1235912B1 (de) | Tumorspezifischer vektor für die gentherapie | |
| DE10056210A1 (de) | Virales Expressionssystem | |
| EP0954592A1 (de) | System zur herstellung von aav-vektoren | |
| DE19707273C1 (de) | Expressionsvektor zur dauerhaften Expression einer Fremd-DNA | |
| WO2003074686A1 (de) | HELFERKONSTRUKTE FÜR DIE HERSTELLUNG HYBRIDER rAAV-PARTIKEL UNTERSCHIEDLICHER AAV-SEROTYPEN | |
| WO1996035797A1 (de) | Hbv-vektoren und zellen zu ihrer bereitstellung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19980930 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| 17Q | First examination report despatched |
Effective date: 20030604 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20051011 |